HRP20211932T1 - Humana antitijela na fel d1 i postupci njihove upotrebe - Google Patents
Humana antitijela na fel d1 i postupci njihove upotrebe Download PDFInfo
- Publication number
- HRP20211932T1 HRP20211932T1 HRP20211932TT HRP20211932T HRP20211932T1 HR P20211932 T1 HRP20211932 T1 HR P20211932T1 HR P20211932T T HRP20211932T T HR P20211932TT HR P20211932 T HRP20211932 T HR P20211932T HR P20211932 T1 HRP20211932 T1 HR P20211932T1
- Authority
- HR
- Croatia
- Prior art keywords
- fel
- cat
- antigen
- human monoclonal
- isolated
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 6
- 239000012634 fragment Substances 0.000 claims 27
- 241000282326 Felis catus Species 0.000 claims 25
- 239000000427 antigen Substances 0.000 claims 20
- 102000036639 antigens Human genes 0.000 claims 20
- 108091007433 antigens Proteins 0.000 claims 20
- 125000003275 alpha amino acid group Chemical group 0.000 claims 12
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 102000004169 proteins and genes Human genes 0.000 claims 8
- 108090000623 proteins and genes Proteins 0.000 claims 8
- 206010020751 Hypersensitivity Diseases 0.000 claims 7
- 208000030961 allergic reaction Diseases 0.000 claims 7
- 230000035945 sensitivity Effects 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 claims 1
- 229930182837 (R)-adrenaline Natural products 0.000 claims 1
- 206010002198 Anaphylactic reaction Diseases 0.000 claims 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 206010070834 Sensitisation Diseases 0.000 claims 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims 1
- 239000013566 allergen Substances 0.000 claims 1
- 201000009961 allergic asthma Diseases 0.000 claims 1
- 208000002205 allergic conjunctivitis Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 208000003455 anaphylaxis Diseases 0.000 claims 1
- 230000001387 anti-histamine Effects 0.000 claims 1
- 239000000739 antihistaminic agent Substances 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000024998 atopic conjunctivitis Diseases 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 239000000850 decongestant Substances 0.000 claims 1
- 229960005139 epinephrine Drugs 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 229940023041 peptide vaccine Drugs 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000008313 sensitization Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16311—Influenzavirus C, i.e. influenza C virus
- C12N2760/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Virology (AREA)
- Otolaryngology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Claims (10)
1. Izolirano humano monoklonsko antitijelo ili njegov fragment koji vezuje antigen koji se specifično veže za alergen mačke Fel d1, gdje:
antitijelo ili fragment koji veže antigen sadrži: (i) HCVR koji ima aminokiselinsku sekvencu SEQ ID NO: 306; i (ii) LCVR koji ima aminokiselinsku sekvencu SEQ ID NO: 314;
i gdje antitijelo ili fragment koji veže antigen je izotip drugačiji od IgA izotipa.
2. Izolirano humano monoklonsko antitijelo ili njegov fragment koji vezuje antigen prema patentnom zahtjevu 1 koje ima izotip koji je izabran iz grupe koja se sastoji iz IgG1, IgG2 i IgG4.
3. Farmaceutski sastav koji sadrži terapeutski efikasnu količinu jednog ili više od izoliranih humanih monoklonskih antitijela, ili njihovih fragmenata koji vezuju antigen, prema patentnom zahtjevu 1 ili 2, koje specifično vezuje Fel d1, zajedno s jednom ili više farmaceutski prihvatljivih pomoćnih tvari.
4. Farmaceutski sastav prema patentnom zahtjevu 3, koji dalje sadrži drugo izolirano humano monoklonsko antitijelo, ili njegov fragment koji vezuje antigen koji se specifično vezuje za Fel d1.
5. Farmaceutski sastav prema patentnom zahtjevu 4, gdje
(i) izolirano drugo humano monoklonsko antitijelo, ili njegov fragment koji se vezuje za antigen koji se specifično veže za Fel d1, sadrži HCVR/LCVR par aminokiselinskih sekvenci izabran iz grupe koju čine SEQ ID NOs: 18/26, 66/74, 130/138, 162/170, 322/330 i 370/378;
(ii) izolirano drugo humano monoklonsko antitijelo, ili njegov fragment koji se vezuje za antigen koji se specifično veže za Fel d1, sadrži HCVR/LCVR par aminokiselinskih sekvenci izabran iz grupe koju čine SEQ ID NOs: 18/26 i 322/330;
(iii) izolirano drugo humano monoklonsko antitijelo ili njegov fragment koji se vezuje za antigen koji se specifično veže za Fel d1, sadrži HCVR/LCVR par aminokiselinskih sekvenci izabran iz grupe koju čine SEQ ID NOs: 66/74;
(iv) izolirano drugo humano monoklonsko antitijelo ili njegov fragment koji se vezuje za antigen koji se specifično veže za Fel d1, sadrži HCVR/LCVR par aminokiselinskih sekvenci izabran iz grupe koju čine SEQ ID NOs: 130/138;
(v) izolirano drugo humano monoklonsko antitijelo ili njegov fragment koji se vezuje za antigen koji se specifično veže za Fel d1, sadrži HCVR/LCVR par aminokiselinskih sekvenci izabran iz grupe koju čine SEQ ID NOs: 322/330;
(vi) izolirano drugo humano monoklonsko antitijelo ili njegov fragment koji se vezuje za antigen koji se specifično veže za Fel d1, sadrži HCVR/LCVR par aminokiselinskih sekvenci izabran iz grupe koju čine SEQ ID NOs: 18/26; ili
(vii) izolirano drugo humano monoklonsko antitijelo ili njegov fragment koji se vezuje za antigen koji se specifično veže za Fel d1, sadrži HCVR/LCVR par aminokiselinskih sekvenci izabran iz grupe koju čine SEQ ID NOs: 370/378.
6. Farmaceutski sastav prema patentnom zahtjevu 4, koja sadrži dva ili više izolirana humana monoklonska antitijela koja se specifično vežu za Fel d1, ili njihove fragmente koji vezuju antigen, pri čemu izolirano drugo humano antitijelo ili njegov fragment koji vezuje antigen koji se veže specifično za Fel d1 sadrži HCVR/LCVR par aminokiselinskih sekvenci izabran iz grupe koju čine SEQ ID NOs: 18/26, 66/74, 130/138, i 162/170.
7. Molekula nukleinske kiseline koja kodira humano monoklonsko antitijelo, ili njegov fragment koji se specifično vezuje za Fel d1 prema patentnom zahtjevu 1 ili 2; ekspresijski vektor koji se sastoji iz molekula nukleinske kiseline; ili stanica domaćina koja sadrži ekspresijski vektor.
8. Efikasna količina jednog ili više od izoliranih humanih monoklonskih antitijela ili njihovih fragmenata koji vezuju antigen koji se specifično vežu za Fel d1, prema patentnom zahtjevu 1 ili 2; ili farmaceutski sastav koji se sastoji iz efikasne količine jednog ili više izoliranih humanih monoklonskih antitijela ili njihovih fragmenata koji se specifično vežu za Fel d1 prema bilo kojem od patentnih zahtjeva 3-6, za upotrebu u postupku za liječenje:
(a) pacijenta koji iskazuje osjetljivost prema, ili alergijsku reakciju protiv, mačke, mačje peruti, mačje dlake ili njenog ekstrakta, ili prema Fel d1 proteinu, spomenuti postupak obuhvaća davanje antitijela, njegovog fragmenta, ili farmaceutskog sastava pacijentu kojem je potrebno, gdje osjetljivost prema, ili alergijska reakcija protiv, mačke, mačje peruti, mačje dlake ili njenog ekstrakta, ili prema Fel d1 proteinu je ili spriječena, ili je smanjena u ozbiljnosti i/ili trajanju, ili da je učestalost i/ili trajanje, ili ozbiljnost osjetljivosti prema ili alergijska reakcija protiv, mačke, mačje peruti, mačje dlake ili njenog ekstrakta, ili prema Fel d1 proteinu je smanjena nakon davanja jednog ili više od izoliranih humanih monoklonskih antitijela ili njihovih fragmenata koji se specifično vežu za Fel d1, ili nakon davanja sastava koji sadrži bilo koje jedno ili više od navedenih antitijela; ili
(b) bar jedan simptom ili komplikacija koja je povezana s osjetljivošću na, ili alergijskom reakcijom protiv mačke, mačje peruti, mačje dlake ili njenog ekstrakta, ili prema Fel d1 proteinu, spomenuti postupak obuhvaća davanje antitijela, njegovog fragmenta, ili farmaceutskog sastava pacijentu kojem je potrebno, gdje bar jedan simptom ili komplikacija koja je povezana s osjetljivošću na, ili alergijskom reakcijom protiv, mačke, mačje peruti, mačje dlake ili njenog ekstrakta, ili prema Fel d1 proteinu je smanjena, ili ublažena, ili da je učestalost i/ili trajanje, ili ozbiljnost osjetljivosti prema ili alergijska reakcija protiv, mačke, mačje peruti, mačje dlake ili njenog ekstrakta, ili prema Fel d1 proteinu smanjena nakon davanja jednog ili više od izoliranih humanih monoklonskih antitijela ili njihovih fragmenata koji se specifično vežu za Fel d1, ili nakon davanja sastava koja sadrži bilo koje jedno ili više od navedenih antitijela.
9. Jedno ili više izoliranih humanih monoklonskih antitijela ili njihovi fragmenti koji vezuju antigen, ili farmaceutski sastav koji sadrži efikasnu količinu jednog ili više od izoliranih humanih monoklonskih antitijela ili njihovih fragmenata koji se specifično vežu za Fel d1, za upotrebu prema postupku pod (a) ili (b) prema patentnom zahtjevu 8:
(a) gdje spomenuti postupak dalje obuhvaća davanje efikasne količine drugog terapeutskog sredstva koje je korisno za smanjenje alergijske reakcije na mačku, mačju perut, mačju dlaku ili njezin ekstrakt, ili na Fel d1 protein, opcionalno gdje drugo terapeutsko sredstvo je izabrano iz grupe koja se sastoji iz kortikosteroida, bronhijalnog dilatatora, antihistamina, epinefrina, dekongestanta, drugog različitog antitijela protiv Fel d1 i peptidnog cjepiva; i/ili
(b) gdje tretman rezultira u smanjenju alergijskog rinitisa, alergijskog konjunktivitisa, alergijske astme, ili anafilaktičke reakcije nakon izlaganja pacijenta mački, mačjoj peruti, mačjoj dlaki ili njenom ekstraktu, ili prema Fel d1 proteinu.
10. Farmaceutski sastav prema patentnom zahtjevu 3 koji se sastoji iz dva ili više izolirana humana monoklonska antitijela koja se specifično vežu za Fel d1, ili njihove fragmente koji vezuju antigen, gdje prvo humano antitijelo ili njegov fragment koji se vezuje za antigen sadrži HCVR/LCVR par aminokiselinske sekvence prema SEQ ID NOs: 306/314, i gdje jedan ili više daljih humanih antitijela ili njihovih fragmenata koji vezuju antigen sadrže HCVR/LCVR parove aminokiselinske sekvence koji su izabrani iz grupe koju čine SEQ ID NOs: 18/26, 66/74, 130/138, i 162/170.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261642083P | 2012-05-03 | 2012-05-03 | |
| US201261718044P | 2012-10-24 | 2012-10-24 | |
| US201361783312P | 2013-03-14 | 2013-03-14 | |
| EP19218187.3A EP3660047B1 (en) | 2012-05-03 | 2013-05-02 | Human antibodies to fel d1 and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20211932T1 true HRP20211932T1 (hr) | 2022-03-18 |
Family
ID=48326501
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20211932TT HRP20211932T1 (hr) | 2012-05-03 | 2013-05-02 | Humana antitijela na fel d1 i postupci njihove upotrebe |
| HRP20200652TT HRP20200652T1 (hr) | 2012-05-03 | 2020-04-23 | Ljudska antitijela na fel d1 i metode njihove primjene |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20200652TT HRP20200652T1 (hr) | 2012-05-03 | 2020-04-23 | Ljudska antitijela na fel d1 i metode njihove primjene |
Country Status (32)
| Country | Link |
|---|---|
| US (6) | US9079948B2 (hr) |
| EP (3) | EP3660047B1 (hr) |
| JP (2) | JP6400569B2 (hr) |
| KR (1) | KR102185516B1 (hr) |
| CN (2) | CN110240651B (hr) |
| AR (1) | AR090914A1 (hr) |
| AU (2) | AU2013256251C1 (hr) |
| BR (2) | BR122019023685B1 (hr) |
| CA (1) | CA2871077C (hr) |
| CY (2) | CY1124023T1 (hr) |
| DK (1) | DK2844672T3 (hr) |
| ES (2) | ES2780392T3 (hr) |
| HK (1) | HK1202123A1 (hr) |
| HR (2) | HRP20211932T1 (hr) |
| HU (2) | HUE057062T2 (hr) |
| IL (1) | IL235121B (hr) |
| IN (1) | IN2014DN08767A (hr) |
| JO (1) | JO3820B1 (hr) |
| LT (2) | LT2844672T (hr) |
| MX (2) | MX2014013371A (hr) |
| MY (3) | MY195564A (hr) |
| NZ (2) | NZ733480A (hr) |
| PL (2) | PL3660047T3 (hr) |
| PT (2) | PT2844672T (hr) |
| RS (2) | RS62636B1 (hr) |
| RU (1) | RU2658491C2 (hr) |
| SG (3) | SG11201406748QA (hr) |
| SI (2) | SI3660047T1 (hr) |
| TW (2) | TW201803901A (hr) |
| UY (1) | UY34782A (hr) |
| WO (1) | WO2013166236A1 (hr) |
| ZA (3) | ZA201407302B (hr) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090137416A1 (en) | 2001-01-16 | 2009-05-28 | Regeneron Pharmaceuticals, Inc. | Isolating Cells Expressing Secreted Proteins |
| US20120204278A1 (en) | 2009-07-08 | 2012-08-09 | Kymab Limited | Animal models and therapeutic molecules |
| DK3622813T3 (da) | 2009-07-08 | 2021-05-03 | Kymab Ltd | Dyremodeller og terapeutiske molekyler |
| ES2612935T3 (es) | 2011-09-19 | 2017-05-19 | Kymab Limited | Anticuerpos, dominios variables y cadenas adaptados para su uso en seres humanos |
| US9253965B2 (en) | 2012-03-28 | 2016-02-09 | Kymab Limited | Animal models and therapeutic molecules |
| US10251377B2 (en) | 2012-03-28 | 2019-04-09 | Kymab Limited | Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies |
| GB2502127A (en) | 2012-05-17 | 2013-11-20 | Kymab Ltd | Multivalent antibodies and in vivo methods for their production |
| JO3820B1 (ar) * | 2012-05-03 | 2021-01-31 | Regeneron Pharma | أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها |
| AR095196A1 (es) | 2013-03-15 | 2015-09-30 | Regeneron Pharma | Medio de cultivo celular libre de suero |
| US9788534B2 (en) | 2013-03-18 | 2017-10-17 | Kymab Limited | Animal models and therapeutic molecules |
| US9783593B2 (en) | 2013-05-02 | 2017-10-10 | Kymab Limited | Antibodies, variable domains and chains tailored for human use |
| US11707056B2 (en) | 2013-05-02 | 2023-07-25 | Kymab Limited | Animals, repertoires and methods |
| CA2922113C (en) * | 2013-08-23 | 2023-05-23 | Regeneron Pharmaceuticals, Inc. | Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (sit) |
| CA2925723A1 (en) | 2013-10-01 | 2015-04-09 | Kymab Limited | Animal models and therapeutic molecules |
| TWI701042B (zh) | 2014-03-19 | 2020-08-11 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| DK3221359T3 (da) | 2014-11-17 | 2020-06-22 | Regeneron Pharma | Fremgangsmåder til tumorbehandling ved anvendelse af CD3XCD20-bispecifikt antistof |
| EP3277725B1 (en) | 2015-03-30 | 2020-11-25 | Regeneron Pharmaceuticals, Inc. | Heavy chain constant regions with reduced binding to fc gamma receptors |
| TW202330904A (zh) | 2015-08-04 | 2023-08-01 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法 |
| NZ740816A (en) * | 2015-09-08 | 2022-05-27 | Univ Zuerich | Compositions against cat allergy |
| WO2017184619A2 (en) | 2016-04-18 | 2017-10-26 | Celldex Therapeutics, Inc. | Agonistic antibodies that bind human cd40 and uses thereof |
| WO2018039499A1 (en) | 2016-08-24 | 2018-03-01 | Regeneron Pharmaceuticals, Inc. | Host cell protein modification |
| US11352417B2 (en) | 2016-12-22 | 2022-06-07 | Regeneron Pharmaceuticals, Inc. | Method of treating an allergy with allergen-specific monoclonal antibodies |
| AU2018212707B2 (en) | 2017-01-24 | 2024-05-09 | Societe Des Produits Nestle S.A. | Compositions comprising anti-Fel D1 antibodies and methods for reducing at least one symptom of human allergy to cats |
| CA3067847A1 (en) | 2017-07-06 | 2019-01-10 | Regeneron Pharmaceuticals, Inc. | Cell culture process for making a glycoprotein |
| CN115925882A (zh) | 2017-12-22 | 2023-04-07 | 瑞泽恩制药公司 | 用于表征药物产品杂质的系统和方法 |
| SG11202005235WA (en) | 2018-01-31 | 2020-07-29 | Regeneron Pharma | System and method for characterizing size and charge variant drug product impurities |
| TW202311746A (zh) | 2018-02-02 | 2023-03-16 | 美商再生元醫藥公司 | 用於表徵蛋白質二聚合之系統及方法 |
| CA3088906A1 (en) | 2018-02-28 | 2019-09-06 | Regeneron Pharmaceuticals, Inc. | Systems and methods for identifying viral contaminants |
| EA202092203A1 (ru) | 2018-03-19 | 2020-12-07 | Ридженерон Фармасьютикалз, Инк. | Способы анализа и реагенты для микрочипового капиллярного электрофореза |
| TW202016125A (zh) | 2018-05-10 | 2020-05-01 | 美商再生元醫藥公司 | 用於定量及調節蛋白質黏度之系統與方法 |
| CA3097194A1 (en) | 2018-05-18 | 2019-11-21 | Chan Zuckerberg Biohub, Inc. | Methods of isolating allergen-specific antibodies from humans and uses thereof |
| KR20210052389A (ko) | 2018-08-27 | 2021-05-10 | 리제너론 파마슈티칼스 인코포레이티드 | 다운스트림 정제에서의 라만 분광법의 사용 |
| WO2020047067A1 (en) | 2018-08-30 | 2020-03-05 | Regeneron Pharmaceuticals, Inc. | Methods for characterizing protein complexes |
| EP4220173A3 (en) | 2019-01-16 | 2023-10-18 | Regeneron Pharmaceuticals, Inc. | Methods for characterizing disulfide bonds |
| SG11202110911RA (en) | 2019-05-13 | 2021-10-28 | Regeneron Pharma | Improved competitive ligand binding assays |
| KR20220066393A (ko) | 2019-09-24 | 2022-05-24 | 리제너론 파아마슈티컬스, 인크. | 크로마토그래피의 사용 및 재생을 위한 시스템 및 방법 |
| IL293112A (en) | 2019-11-25 | 2022-07-01 | Regeneron Pharma | Sustained release formulations using non-aqueous emulsions |
| WO2021150558A1 (en) | 2020-01-21 | 2021-07-29 | Regeneron Pharmaceuticals, Inc. | Deglycosylation methods for electrophoresis of glycosylated proteins |
| WO2022046925A1 (en) | 2020-08-26 | 2022-03-03 | Regeneron Pharmaceuticals, Inc. | Method of treating an allergy with allergen-specific monoclonal antibodies |
| BR112023003273A2 (pt) | 2020-08-31 | 2023-05-02 | Regeneron Pharma | Estratégias de alimentação de asparagina para melhorar desempenho da cultura celular e mitigar variantes da sequência de asparagina |
| KR20230113280A (ko) | 2020-11-25 | 2023-07-28 | 리제너론 파마슈티칼스 인코포레이티드 | 비수성 멤브레인 유화법을 사용한 지속 방출 제형 |
| WO2022133135A1 (en) | 2020-12-17 | 2022-06-23 | Regeneron Pharmaceuticals, Inc. | Fabrication of protein-encapsulating microgels |
| KR20230134117A (ko) | 2021-01-20 | 2023-09-20 | 리제너론 파마슈티칼스 인코포레이티드 | 세포 배양물에서 단백질 역가를 개선시키는 방법 |
| WO2022187323A1 (en) | 2021-03-03 | 2022-09-09 | Regeneron Pharmaceuticals, Inc. | Systems and methods for quantifying and modifying protein viscosity |
| CA3211302A1 (en) | 2021-03-26 | 2022-09-29 | Ross Kenyon | Methods and systems for developing mixing protocols |
| KR20240015646A (ko) | 2021-06-01 | 2024-02-05 | 리제너론 파마슈티칼스 인코포레이티드 | 마이크로칩 모세관 전기영동 분석 및 시약 |
| AR127006A1 (es) | 2021-09-08 | 2023-12-06 | Regeneron Pharma | UN MÉTODO BASADO EN ESPECTROMETRÍA DE MASAS Y DE ALTO RENDIMIENTO PARA CUANTIFICAR ANTICUERPOS Y OTRAS PROTEÍNAS QUE CONTIENEN Fc |
| KR20240058201A (ko) | 2021-09-20 | 2024-05-03 | 리제너론 파마슈티칼스 인코포레이티드 | 항체 이질성을 제어하는 방법 |
| AU2022359898A1 (en) | 2021-10-07 | 2024-03-21 | Regeneron Pharmaceuticals, Inc. | Ph meter calibration and correction |
| TW202323817A (zh) | 2021-10-07 | 2023-06-16 | 美商再生元醫藥公司 | Ｐｈ建模及控制之系統及方法 |
| CA3236367A1 (en) | 2021-10-26 | 2023-05-04 | Michelle Lafond | Systems and methods for generating laboratory water and distributing laboratory water at different temperatures |
| CN114113278A (zh) * | 2021-11-24 | 2022-03-01 | 中国计量科学研究院 | 一种基于质谱的体外诊断试剂抗体的表位定位方法 |
| TW202346856A (zh) | 2022-03-18 | 2023-12-01 | 美商里珍納龍藥品有限公司 | 分析多肽變體的方法及系統 |
| US20230416349A1 (en) | 2022-06-23 | 2023-12-28 | Regeneron Pharmaceuticals, Inc. | Methods Of Identifying And Evaluating Cat Allergy Gene Signatures In A Subject By Determining A Stratified Score Based On Gene Expression |
| CN117004650B (zh) * | 2023-06-25 | 2024-05-14 | 山东立菲生物产业有限公司 | 一种猫皮屑过敏原组分feld1双链二聚体重组蛋白、制备方法及应用 |
| CN117069865B (zh) * | 2023-10-12 | 2024-03-01 | 中国农业科学院饲料研究所 | 一种基于T细胞抗原表位猫过敏原蛋白嵌合肽cFel d 1的原核表达及其卵黄抗体的制备 |
| CN117964767A (zh) * | 2024-03-29 | 2024-05-03 | 北京恩泽康泰生物科技有限公司 | 抗rage抗体、细胞外囊泡及其制备方法和应用 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993013772A1 (en) | 1992-01-21 | 1993-07-22 | Immulogic Pharmaceutical Corporation | Methods for using histamine derivatives as immunomodulators and in immunotherapeutics |
| AU5958494A (en) * | 1992-12-21 | 1994-07-19 | Tanox Biosystems, Inc. | Allergen-specific iga monoclonal antibodies and related products for allergy treatment |
| GB0002386D0 (en) | 2000-02-02 | 2000-03-22 | Novartis Nutrition Ag | Therapeutic composition |
| US6849259B2 (en) | 2000-06-16 | 2005-02-01 | Symphogen A/S | Polyclonal antibody composition for treating allergy |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| US7850962B2 (en) | 2004-04-20 | 2010-12-14 | Genmab A/S | Human monoclonal antibodies against CD20 |
| PT1868642E (pt) * | 2005-03-18 | 2013-07-10 | Cytos Biotechnology Ag | Proteínas de fusão de alergénios de gato e suas utilizações |
| US7566456B2 (en) * | 2005-06-23 | 2009-07-28 | Haiming Chen | Allergen vaccine proteins for the treatment and prevention of allergic diseases |
| GB0513878D0 (en) * | 2005-07-06 | 2005-08-10 | Mars Inc | Cat allergen |
| WO2007065633A1 (en) | 2005-12-05 | 2007-06-14 | Imvision Ag | Modulation of the immune response by administration of intralymphatic transduction allergen (itag) -molecules |
| WO2007113633A2 (en) | 2006-04-03 | 2007-10-11 | Pfizer Products Inc. | Immunogenic compositions comprising cat allergen fel dl |
| MY159787A (en) | 2006-06-02 | 2017-01-31 | Regeneron Pharma | High affinity antibodies to human il-6 receptor |
| AT503690A1 (de) | 2006-06-09 | 2007-12-15 | Biomay Ag | Hypoallergene moleküle |
| EP1921142A1 (en) * | 2006-11-07 | 2008-05-14 | Cytos Biotechnology AG | Selection of human monoclonal antibodies by eukaryotic cell display |
| RU2448979C2 (ru) | 2006-12-14 | 2012-04-27 | Ридженерон Фармасьютикалз, Инк. | Антитела человека к дельта-подобному лиганду-4 человека |
| CN104497143B (zh) * | 2007-03-29 | 2020-08-25 | 健玛保 | 双特异性抗体及其制造方法 |
| US20100267934A1 (en) * | 2007-05-31 | 2010-10-21 | Genmab A/S | Stable igg4 antibodies |
| GB0710529D0 (en) | 2007-06-01 | 2007-07-11 | Circassia Ltd | Vaccine |
| CN101686974A (zh) * | 2007-07-09 | 2010-03-31 | 雀巢产品技术援助有限公司 | 减轻因环境过敏原导致的过敏症的方法 |
| WO2009023540A1 (en) | 2007-08-10 | 2009-02-19 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human nerve growth factor |
| JO3340B1 (ar) * | 2010-05-26 | 2019-03-13 | Regeneron Pharma | مضادات حيوية لـعامل تمايز النمو 8 البشري |
| JO3820B1 (ar) * | 2012-05-03 | 2021-01-31 | Regeneron Pharma | أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها |
-
2013
- 2013-05-01 JO JOP/2013/0131A patent/JO3820B1/ar active
- 2013-05-02 US US13/875,401 patent/US9079948B2/en active Active
- 2013-05-02 DK DK13721544.8T patent/DK2844672T3/da active
- 2013-05-02 MY MYPI2020006733A patent/MY195564A/en unknown
- 2013-05-02 CA CA2871077A patent/CA2871077C/en active Active
- 2013-05-02 LT LTEP13721544.8T patent/LT2844672T/lt unknown
- 2013-05-02 SI SI201331935T patent/SI3660047T1/sl unknown
- 2013-05-02 NZ NZ733480A patent/NZ733480A/en unknown
- 2013-05-02 HR HRP20211932TT patent/HRP20211932T1/hr unknown
- 2013-05-02 NZ NZ701124A patent/NZ701124A/en unknown
- 2013-05-02 SG SG11201406748QA patent/SG11201406748QA/en unknown
- 2013-05-02 ES ES13721544T patent/ES2780392T3/es active Active
- 2013-05-02 IN IN8767DEN2014 patent/IN2014DN08767A/en unknown
- 2013-05-02 PT PT137215448T patent/PT2844672T/pt unknown
- 2013-05-02 MY MYPI2017701565A patent/MY181422A/en unknown
- 2013-05-02 WO PCT/US2013/039192 patent/WO2013166236A1/en active Application Filing
- 2013-05-02 KR KR1020147033137A patent/KR102185516B1/ko active IP Right Grant
- 2013-05-02 RS RS20211475A patent/RS62636B1/sr unknown
- 2013-05-02 TW TW106119738A patent/TW201803901A/zh unknown
- 2013-05-02 PT PT192181873T patent/PT3660047T/pt unknown
- 2013-05-02 EP EP19218187.3A patent/EP3660047B1/en active Active
- 2013-05-02 PL PL19218187T patent/PL3660047T3/pl unknown
- 2013-05-02 CN CN201910294004.8A patent/CN110240651B/zh active Active
- 2013-05-02 ES ES19218187T patent/ES2898372T3/es active Active
- 2013-05-02 CN CN201380035000.9A patent/CN104411719B/zh active Active
- 2013-05-02 SG SG10202102919XA patent/SG10202102919XA/en unknown
- 2013-05-02 LT LTEP19218187.3T patent/LT3660047T/lt unknown
- 2013-05-02 AU AU2013256251A patent/AU2013256251C1/en active Active
- 2013-05-02 RS RS20200539A patent/RS60282B1/sr unknown
- 2013-05-02 EP EP13721544.8A patent/EP2844672B1/en active Active
- 2013-05-02 JP JP2015510445A patent/JP6400569B2/ja active Active
- 2013-05-02 TW TW102115645A patent/TWI644921B/zh active
- 2013-05-02 SG SG10201608378UA patent/SG10201608378UA/en unknown
- 2013-05-02 SI SI201331698T patent/SI2844672T1/sl unknown
- 2013-05-02 PL PL13721544T patent/PL2844672T3/pl unknown
- 2013-05-02 BR BR122019023685-2A patent/BR122019023685B1/pt active IP Right Grant
- 2013-05-02 EP EP21194412.9A patent/EP3978522A3/en active Pending
- 2013-05-02 AR ARP130101494 patent/AR090914A1/es unknown
- 2013-05-02 HU HUE19218187A patent/HUE057062T2/hu unknown
- 2013-05-02 BR BR112014026852-5A patent/BR112014026852B1/pt active IP Right Grant
- 2013-05-02 MX MX2014013371A patent/MX2014013371A/es active IP Right Grant
- 2013-05-02 RU RU2014148502A patent/RU2658491C2/ru active
- 2013-05-02 MY MYPI2014002857A patent/MY164101A/en unknown
- 2013-05-02 HU HUE13721544A patent/HUE049440T2/hu unknown
- 2013-05-03 UY UY34782A patent/UY34782A/es active IP Right Grant
-
2014
- 2014-10-08 ZA ZA2014/07302A patent/ZA201407302B/en unknown
- 2014-10-19 IL IL235121A patent/IL235121B/en active IP Right Grant
- 2014-11-03 MX MX2020003864A patent/MX2020003864A/es unknown
-
2015
- 2015-03-13 HK HK15102575.2A patent/HK1202123A1/xx unknown
- 2015-06-05 US US14/732,578 patent/US9475869B2/en active Active
-
2016
- 2016-09-13 US US15/263,848 patent/US10047152B2/en active Active
-
2017
- 2017-01-26 US US15/416,176 patent/US10047153B2/en active Active
- 2017-06-14 JP JP2017116808A patent/JP6603269B2/ja active Active
-
2018
- 2018-05-03 AU AU2018203087A patent/AU2018203087B9/en active Active
- 2018-07-05 US US16/028,275 patent/US11174305B2/en active Active
-
2020
- 2020-04-23 HR HRP20200652TT patent/HRP20200652T1/hr unknown
- 2020-05-04 CY CY20201100408T patent/CY1124023T1/el unknown
- 2020-08-25 ZA ZA2020/05273A patent/ZA202005273B/en unknown
-
2021
- 2021-10-13 US US17/500,418 patent/US20220025029A1/en active Pending
- 2021-12-20 CY CY20211101115T patent/CY1124819T1/el unknown
-
2022
- 2022-03-09 ZA ZA2022/02846A patent/ZA202202846B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20200652T1 (hr) | Ljudska antitijela na fel d1 i metode njihove primjene | |
| JP2015523962A5 (hr) | ||
| HRP20200846T1 (hr) | Anti-il-33 antitijela i njihove primjene | |
| ES2900342T3 (es) | Métodos para tratar o prevenir el asma administrando un antagonista de IL-4R | |
| Hoffman | Therapy of autoinflammatory syndromes | |
| KR102492826B1 (ko) | Il-4r 억제제를 투여함으로써 알레르기 치료 및 알레르겐 특이적 면역요법을 강화시키는 방법 | |
| CN105517570B (zh) | 通过施用il-4r拮抗剂治疗鼻息肉症的方法 | |
| JP2019531273A5 (hr) | ||
| TW200808821A (en) | Antibody purification | |
| RU2749512C2 (ru) | Фармацевтическая композиция для профилактики и/или лечения атопического дерматита, включающая антагонист ил-31 в качестве активного ингредиента | |
| HRP20140661T1 (hr) | Apoptotiäśka protutijela anti-ige koja vežu ige spojen s membranom | |
| TW201206478A (en) | Multiple-variable dose regimen for treating TNF α -related disorders | |
| TW200412998A (en) | Treatment of TNF α related disorders | |
| RU2668802C2 (ru) | Антитела, используемые для пассивной вакцинации против гриппа | |
| JP6554155B2 (ja) | Ｉｌ−１７アンタゴニストを使用して汎発性膿疱性乾癬（ｇｐｐ）を処置する方法 | |
| EP3229829B1 (en) | Method for the treatment of idiopathic pulmonary fibrosis | |
| JP2022543815A (ja) | Ｉｌ－４ｒアンタゴニストを投与することによりアレルギーを治療しアレルゲン特異的免疫療法を増強するための方法 | |
| JP7162097B2 (ja) | Ｂｅｔ ｖ １に対するヒト抗体およびその使用方法 | |
| EP3564671B1 (en) | Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (sit) | |
| CA3173173A1 (en) | Methods for treating atopic dermatitis by administering an il-4r antagonist | |
| JP2021112207A5 (hr) | ||
| Dimov et al. | Immunomodulators for asthma | |
| Wechsler et al. | Preclinical and clinical experience with dupilumab on the correlates of live attenuated vaccines | |
| Albrecht | Turning off the alarm–Targeting alarmins and other epithelial mediators of allergic inflammation with biologics | |
| WO2023061390A1 (en) | Treatment of ige-mediated diseases |